Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 1/2018

01-01-2018 | Review

Microbiota Signaling Pathways that Influence Neurologic Disease

Authors: Laura M. Cox, Howard L. Weiner

Published in: Neurotherapeutics | Issue 1/2018

Login to get access

Abstract

Though seemingly distinct and autonomous, emerging evidence suggests there is a bidirectional interaction between the intestinal microbiota and the brain. This crosstalk may play a substantial role in neurologic diseases, including anxiety, depression, autism, multiple sclerosis, Parkinson’s disease, and, potentially, Alzheimer’s disease. Long hypothesized by Metchnikoff and others well over 100 years ago, investigations into the mind–microbe axis is now seeing a rapid resurgence of research. If specific pathways and mechanisms of interaction are understood, it could have broad therapeutic potential, as the microbiome is environmentally acquired and can be modified to promote health. This review will discuss immune, endocrine, and neural system pathways that interconnect the gut microbiota to central nervous system and discuss how these findings might be applied to neurologic disease.
Appendix
Available only for authorised users
Literature
1.
Sender, R., S. Fuchs, and R. Milo. Are we really vastly outnumbered? revisiting the ratio of bacterial to host cells in humans. Cell 2016; 164(3): p. 337-340.PubMedCrossRef
2.
3.
Laukens, D., B.M. Brinkman, J. Raes, M. De Vos, and P. Vandenabeele, Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design. FEMS Microbiol. Rev., 2016. 40(1): p. 117-132.PubMedCrossRef
4.
Tremaroli, V. and F. Bäckhed, Functional interactions between the gut microbiota and host metabolism. Nature, 2012. 489(7415): p. 242-249.PubMedCrossRef
5.
6.
Belkaid, Y. and O.J. Harrison, Homeostatic immunity and the microbiota. Immunity, 2017. 46(4): p. 562-576.PubMedCrossRef
7.
8.
Collins, S.M., M. Surette, and P. Bercik, The interplay between the intestinal microbiota and the brain. Nature Rev Microbiol, 2012. 10(11): p. 735-742.CrossRef
9.
Markle, J.G.M., D.N. Frank, S. Mortin-Toth, et al., Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science, 2013. 339(6123): p. 1084-1088.PubMedCrossRef
10.
Sayin, S.I., A. Wahlström, J. Felin, et al., Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab, 2013. 17(2): p. 225-235.PubMedCrossRef
11.
Haiser, H.J. and P.J. Turnbaugh, Is it time for a metagenomic basis of therapeutics? Science, 2012. 336(6086): p. 1253-1255.PubMedCrossRef
12.
Yatsunenko, T., F.E. Rey, M.J. Manary, et al., Human gut microbiome viewed across age and geography. Nature, 2012. 486: p. 222-227.PubMedPubMedCentral
13.
14.
Wassenaar, T. and P. Panigrahi, Is a foetus developing in a sterile environment? Lett Appl Microbiol 2014. 59(6): p. 572-579.PubMedCrossRef
15.
Fardini, Y., P. Chung, R. Dumm, N. Joshi, and Y.W. Han, Transmission of diverse oral bacteria to murine placenta: evidence for the oral microbiome as a potential source of intrauterine infection. Infect Immun, 2010. 78(4): p. 1789-1796.PubMedPubMedCentralCrossRef
16.
17.
Dominguez-Bello, M.G., E.K. Costello, M. Contreras, et al., Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A, 2010. 107(26): p. 11971-11975.PubMedPubMedCentralCrossRef
18.
Zeissig, S. and R.S. Blumberg, Life at the beginning: perturbation of the microbiota by antibiotics in early life and its role in health and disease. Nat Immunol, 2014. 15(4): p. 307-310.PubMedCrossRef
19.
Cox, L.M., S. Yamanishi, J. Sohn, et al., Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell, 2014. 158(4): p. 705-721.PubMedPubMedCentralCrossRef
20.
Chung, H., S.J. Pamp, J.A. Hill, et al., Gut immune maturation depends on colonization with a host-specific microbiota. Cell, 2012. 149(7): p. 1578-1593.PubMedPubMedCentralCrossRef
21.
Walker, W.A., Initial intestinal colonization in the human infant and immune homeostasis. Ann Nutr Metab, 2013. 63(s2): p. 8-15.PubMedCrossRef
22.
Borre, Y.E., G.W. O’Keeffe, G. Clarke, et al., Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med 2014. 20(9): p. 509-518.PubMedCrossRef
23.
Stilling, R.M., T.G. Dinan, and J.F. Cryan, Microbial genes, brain & behaviour—epigenetic regulation of the gut–brain axis. Genes Brain Behav 2013. 13(1): p. 69-86.PubMedCrossRef
24.
Spor, A., O. Koren, and R. Ley, Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011. 9(4): p. 279-290.PubMedCrossRef
25.
Dąbrowska, K. and W. Witkiewicz, Correlations of host genetics and gut microbiome composition. Front Microbiol 2016. 7(1357).
26.
Ridaura, V.K., J.J. Faith, F.E. Rey, et al., Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 2013. 341(6150): p. 1079.CrossRef
27.
Sommer, F. and F. Bäckhed, The gut microbiota—masters of host development and physiology. Nat Rev Microbiol 2013. 11: p. 227.PubMedCrossRef
28.
Costello, E., C. Lauber, M. Hamady, et al., Bacterial community variation in human body habitats across space and time. Science, 2009. 326: p. 1694-1697.PubMedPubMedCentralCrossRef
29.
Costello, E.K., K. Stagaman, L. Dethlefsen, B.J.M. Bohannan, and D.A. Relman, The application of ecological theory toward an understanding of the human microbiome. Science, 2012. 336(6086): p. 1255-1262.PubMedPubMedCentralCrossRef
30.
David, L.A., C.F. Maurice, R.N. Carmody, et al., Diet rapidly and reproducibly alters the human gut microbiome. Nature, 2014. 505(7484): p. 559-563.PubMedCrossRef
31.
32.
Levy, M., A.A. Kolodziejczyk, C.A. Thaiss, and E. Elinav, Dysbiosis and the immune system. Nat Rev Immunol 2017; 17: 219-232.PubMedCrossRef
33.
Dethlefsen, L., S. Huse, M.L. Sogin, and D.A. Relman, The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLOS Biol, 2008. 6(11): p. e280.
34.
Matamoros, S., C. Gras-Leguen, F. Le Vacon, G. Potel, and M.-F. de La Cochetiere, Development of intestinal microbiota in infants and its impact on health. Trends Microbiol 2013. 21(4): p. 167-173.PubMedCrossRef
35.
Samuel, B.S., A. Shaito, T. Motoike, et al., Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A, 2008. 105(43): p. 16767-16772.PubMedPubMedCentralCrossRef
36.
Clemmensen, C., T.D. Müller, S.C. Woods, et al., Gut–brain cross-talk in metabolic control. Cell, 2017. 168(5): p. 758-774.PubMedCrossRef
37.
38.
Cryan, J.F. and T.G. Dinan, Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012. 13(10): p. 701-712.PubMedCrossRef
39.
Foster, J.A. and K.-A.M. Neufeld, Gut–brain axis: how the microbiome influences anxiety and depression. Trends Neurosci, 2013. 36(5): p. 305-312.PubMedCrossRef
40.
Bravo, J.A., P. Forsythe, M.V. Chew, et al., Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A 2011. 108(38): p. 16050-16055.PubMedPubMedCentralCrossRef
41.
Bercik, P., A.J. Park, D. Sinclair, et al., The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut–brain communication. Neurogastroenterol Motil 2011. 23(12): p. 1132-1139.PubMedPubMedCentralCrossRef
42.
Kunze, W.A., Y.K. Mao, B. Wang, et al., Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J Cell Mol Med 2009. 13(8b): p. 2261-2270.PubMedCrossRef
43.
Bellono, N.W., J.R. Bayrer, D.B. Leitch, et al., Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell, 2017. 170(1): p. 185-198. e16.PubMedCrossRef
44.
Brierley, S.M. and D.R. Linden, Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat Rev Gastroenterol Hepatol 2014. 11(10): p. 611-627.PubMedCrossRef
45.
Farup, P.G., K. Rudi, and K. Hestad, Faecal short-chain fatty acids-a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol 2016. 16(1): p. 51.PubMedPubMedCentralCrossRef
46.
Tanaka, K., M. Budd, M. Efron, and K. Isselbacher, Isovaleric acidemia: a new genetic defect of leucine metabolism. Proc Natl Acad Sci U S A 1966. 56(1): p. 236-242.PubMedPubMedCentralCrossRef
47.
Fujinaga, Y., Y. Sugawara, and T. Matsumura. Uptake of botulinum neurotoxin in the intestine, in botulinum neurotoxins, A. Rummel and T. Binz, Editors. 2013, Springer Berlin Heidelberg: Berlin, Heidelberg. p. 45–59.
48.
Brown, N. and S. Desai, Infantile botulism: a case report and review. J Emerg Med 2013. 45(6): p. 842-845.PubMedCrossRef
49.
Sudo, N., Y. Chida, Y. Aiba, et al., Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice. J Physiol 2004. 558(1): p. 263-275.PubMedPubMedCentralCrossRef
50.
Webster Marketon, J. and E. Sternberg, The glucocorticoid receptor: a revisited target for toxins. Vol. 2. 2010. 1357-80.
51.
Reichardt, H.M., T. Umland, A. Bauer, O. Kretz, and G. Schütz, Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol Cell Biol 2000. 20(23): p. 9009-9017.PubMedPubMedCentralCrossRef
52.
Wang, Y. and L.H. Kasper, The role of microbiome in central nervous system disorders. Brain Behav Immun 2014. 38(C): p. 1-12.PubMedCrossRef
53.
Ichimura, A., A. Hirasawa, T. Hara, and G. Tsujimoto, Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis. Prostaglandins Other Lipid Mediat, 2009. 89: p. 82-8.PubMedCrossRef
54.
Honda, K. and D.R. Littman, The microbiota in adaptive immune homeostasis and disease. Nature, 2016. 535(7610): p. 75-84.PubMedCrossRef
55.
Kamada, N., S.-U. Seo, G.Y. Chen, and G. Núñez, Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol, 2013. 13(5): p. 321-335.PubMedCrossRef
56.
57.
Ivanov, I.I. and D.R. Littman, Segmented filamentous bacteria take the stage. Mucosal Immunol 2010: p. 209–212.
58.
Atarashi, K.,T. Tanoue, T. Shima, et al., Induction of colonic regulatory T cells by indigenous Clostridium species. Science, 2011. 331(6015): p. 337-341.PubMedCrossRef
59.
Round, J.L. and S.K. Mazmanian, Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci 2010. 107(27): p. 12204-12209.PubMedPubMedCentralCrossRef
60.
61.
Robinson, K., R.H. Argent, and J.C. Atherton, The inflammatory and immune response to Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007. 21(2): p. 237-259.PubMedCrossRef
62.
Parsot, C. and P.J. Sansonetti, The virulence plasmid of Shigellae: an archipelago of pathogenicity islands?, in Pathogenicity islands and other mobile virulence elements. 1999, American Society of Microbiology. p. 151-165.
63.
Kaper, J.B., J.L. Mellies, and J.P. Nataro, Pathogenicity islands and other mobile genetic elements of diarrheagenic Escherichia coli, in Pathogenicity islands and other mobile virulence elements. 1999, American Society of Microbiology. p. 33-58.
64.
Hill, K.K., G. Xie, B.T. Foley, and T.J. Smith, Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins. Toxicon, 2015. 107(Part A): p. 2-8.PubMedCrossRef
65.
66.
Louis, P. and H.J. Flint, Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol 2017. 19(1): p. 29-41.PubMedCrossRef
67.
Wong, J.M.W., R. de Souza, C.W.C. Kendall, A. Emam, and D.J.A. Jenkins, Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol, 2006. 40(3): p. 235-43.PubMedCrossRef
68.
Koh, A., F. De Vadder, P. Kovatcheva-Datchary, and F. Bäckhed, From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell, 2016. 165(6): p. 1332-1345.PubMedCrossRef
69.
Louis, P. and H.J. Flint, Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett, 2009. 294(1): p. 1-8.PubMedCrossRef
70.
Erny, D., A.L.H. de Angelis, D. Jaitin, et al., Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 2015. 18(7): p. 965-977.
71.
Chang, P.V., L. Hao, S. Offermanns, and R. Medzhitov, The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci, 2014. 111(6): p. 2247-2252.PubMedPubMedCentralCrossRef
72.
Singh, N., A. Gurav, S. Sivaprakasam, et al., Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity, 2014. 40(1): p. 128-139.PubMedPubMedCentralCrossRef
73.
Sampson, T.R., J.W. Debelius, T. Thron, et al., Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell, 2016. 167(6): p. 1469-1480. e12.PubMedPubMedCentralCrossRef
74.
Prinz, M. and J. Priller, Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 2014. 15(5): p. 300-312.PubMedCrossRef
75.
Rothhammer, V., I.D. Mascanfroni, L. Bunse, et al., Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and CNS inflammation via the aryl hydrocarbon receptor. Nat Med, 2016. 22(6): p. 586.PubMedPubMedCentralCrossRef
76.
Rothhammer, V. and F.J. Quintana, Environmental control of autoimmune inflammation in the central nervous system. Curr Opin Immunol, 2016. 43: p. 46-53.PubMedPubMedCentralCrossRef
77.
Myint, A.-M., Y.K. Kim, R. Verkerk, et al., Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007. 98(1): p. 143-151.PubMedCrossRef
78.
Clarke, G., S. Grenham, P. Scully, et al., The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry, 2013. 18(6): p. 666.PubMedCrossRef
79.
Desbonnet, L., G. Clarke, A. Traplin, et al., Gut microbiota depletion from early adolescence in mice: implications for brain and behaviour. Brain Behav Immun, 2015. 48: p. 165-173.PubMedCrossRef
80.
Berer, K., M. Mues, M. Koutrolos, et al., Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature, 2011. 479(7374): p. 538.PubMedCrossRef
81.
Lee, Y.K., J.S. Menezes, Y. Umesaki, and S.K. Mazmanian, Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A, 2011. 108(Suppl. 1): p. 4615-4622.PubMedCrossRef
82.
Ochoa-Reparaz, J., D.W. Mielcarz, L.E. Ditrio, et al., Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol 2009. 183(10): p. 6041-6050.PubMedCrossRef
83.
Yokote, H., S. Miyake, J.L. Croxford, et al., NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 2010. 173(6): p. 1714-1723.CrossRef
84.
Colpitts, S.L., E.J. Kasper, A. Keever, et al., A bidirectional association between the gut microbiota and CNS disease in a biphasic murine model of multiple sclerosis. Gut Microbes, 2017. 137(5): p. 561-573.
85.
Alonso, A., Antibiotic use and risk of multiple sclerosis. Am J Epidemiol, 2006. 163(11): p. 997-1002.PubMedCrossRef
86.
Norgaard, M., R.B. Nielsen, J.B. Jacobsen, et al., Use of penicillin and other antibiotics and risk of multiple sclerosis: a population-based case-control study. Am J Epidemiol, 2011. 174(8): p. 945-948.PubMedCrossRef
87.
Ren, J., H. Ni, M. Kim, et al., Allergies, antibiotics use, and multiple sclerosis. Curr Med Res Opin 2017. 167: p. 1-6.
88.
89.
Miyake, S., S. Kim, W. Suda, et al., Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLOS ONE, 2015. 10(9): p. e0137429.
90.
Cantarel, B.L., E. Waubant, C. Chehoud, et al., Gut microbiota in multiple sclerosis. J Invest Med, 2015. 63(5): p. 729-734.CrossRef
91.
Chen, J., N. Chia, K.R. Kalari, et al., Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep 2016. 6.
92.
van Passel, M.W.J., R. Kant, E.G. Zoetendal, et al., The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes. PLOS ONE, 2011. 6(3): p. e16876.
93.
Everard, A., C. Belzer, L. Geurts, et al., Crosstalk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A, 2013. 110(22): p. 9066-9071.PubMedPubMedCentralCrossRef
94.
Derrien, M., E.E. Vaughan, C.M. Plugge, and W.M. de Vos, Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Micr, 2004. 54(5): p. 1469-1476.CrossRef
95.
Dubourg, G., F. Cornu, S. Edouard, et al., First isolation of Akkermansia muciniphila in a blood-culture sample. Clin Microbiol Infect 2017;23:682-683.PubMedCrossRef
96.
Blais Lecours, P., C. Duchaine, M. Taillefer, et al., Immunogenic properties of archaeal species found in bioaerosols. PLOS ONE, 2011. 6(8): p. e23326.
97.
Verma, R., A.K. Verma, V. Ahuja, and J. Paul, Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. J Clin Microbiol 2010. 48(11): p. 4279-4282.PubMedPubMedCentralCrossRef
98.
Samuel, B.S., E.E. Hansen, J.K. Manchester, et al., Genomic and metabolic adaptations of Methanobrevibacter smithii to the human gut. Proc Natl Acad Sci U S A 2007. 104(25): p. 10643-10648.PubMedPubMedCentralCrossRef
99.
Yamabe, K., H. Maeda, S. Kokeguchi, et al., Distribution of Archaea in Japanese patients with periodontitis and humoral immune response to the components. FEMS Microbiol Lett 2008. 287(1): p. 69-75.PubMedCrossRef
100.
Krishnan, L., S. Sad, G.B. Patel, and G.D. Sprott, The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo. J Immunol 2001. 166(3): p. 1885-1893.PubMedCrossRef
101.
Berer, K., L.A. Gerdes, E. Cekanaviciute, et al., Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A, 2017. 114(40): p. 10719-10724.PubMedPubMedCentralCrossRef
102.
Cekanaviciute, E., B.B. Yoo, T.F. Runia, et al., Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A, 2017: p. 201711235.
103.
Fasano, A., N.P. Visanji, L.W. Liu, A.E. Lang, and R.F. Pfeiffer, Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2015. 14(6): p. 625-639.PubMedCrossRef
104.
Houser, M.C. and M.G. Tansey, The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? NPJ Parkinson's Disease, 2017. 3: p. 1.CrossRef
105.
Chen, H., E.J. Zhao, W. Zhang, et al., Meta-analyses on prevalence of selected Parkinson’s nonmotor symptoms before and after diagnosis. Transl Neurodegener, 2015. 4(1): p. 1.PubMedPubMedCentralCrossRef
106.
Shannon, K.M., A. Keshavarzian, H.B. Dodiya, S. Jakate, and J.H. Kordower, Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases. Mov Disord 2012. 27(6): p. 716-719.PubMedCrossRef
107.
Unger, M.M., J. Spiegel, K.-U. Dillmann, et al., Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord 2016. 32: p. 66-72.PubMedCrossRef
108.
Hasegawa, S., S. Goto, H. Tsuji, et al., Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease. PLOS ONE, 2015. 10(11): p. e0142164.
109.
Scheperjans, F., V. Aho, P.A. Pereira, et al., Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015. 30(3): p. 350-358.PubMedCrossRef
110.
Keshavarzian, A., S.J. Green, P.A. Engen, et al., Colonic bacterial composition in Parkinson's disease. Mov Disord 2015. 30(10): p. 1351-1360.PubMedCrossRef
111.
Bercik, P., E. Denou, J. Collins, et al., The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology, 2011. 141(2): p. 599-609.e3.PubMedCrossRef
112.
Sylvia, K.E., C.P. Jewell, N.M. Rendon, E.A. St. John, and G.E. Demas, Sex-specific modulation of the gut microbiome and behavior in Siberian hamsters. Brain Behav Immun 2017. 60(Supplement C): p. 51-62.PubMedCrossRef
113.
Autism and Development Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders: autism and developmental disabilities monitoring network, 14 sites, United States, 2008. MMWR Surveill Summ 2012;61:1-19.
114.
Sandler, R.H., S.M. Finegold, E.R. Bolte, et al., Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000. 15(7): p. 429-435.PubMedCrossRef
115.
Kohane, I.S., A. McMurry, G. Weber, et al., The co-morbidity burden of children and young adults with autism spectrum disorders. PLOS ONE, 2012. 7(4): p. e33224.
116.
Adams, J.B., L.J. Johansen, L.D. Powell, D. Quig, and R.A. Rubin, Gastrointestinal flora and gastrointestinal status in children with autism–comparisons to typical children and correlation with autism severity. BMC Gastroenterol, 2011. 11(1): p. 22.PubMedPubMedCentralCrossRef
117.
Hsiao, E.Y., S.W. McBride, S. Hsien, et al., Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell, 2013: p. 1451-63.
118.
Mazmanian, S.K., J.L. Round, and D.L. Kasper, A microbial symbiosis factor prevents intestinal inflammatory disease. Nature, 2008. 453(7195): p. 620.PubMedCrossRef
Metadata
Title
Microbiota Signaling Pathways that Influence Neurologic Disease
Authors
Laura M. Cox
Howard L. Weiner
Publication date
01-01-2018
Publisher
Springer US
Published in
Neurotherapeutics / Issue 1/2018
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-017-0598-8

Other articles of this Issue 1/2018

Neurotherapeutics 1/2018 Go to the issue

Review

The Gut Microbiota and Pediatric Multiple Sclerosis: Recent Findings

Review

The “Gut Feeling”: Breaking Down the Role of Gut Microbiome in Multiple Sclerosis

Original Article

Chronic Fluoxetine Induces Activity Changes in Recovery From Poststroke Anxiety, Depression, and Cognitive Impairment

Review

The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the “MS Microbiome”

Current Perspectives

S-Adenosyl Methionine and Transmethylation Pathways in Neuropsychiatric Diseases Throughout Life

Review

Anxiety, Depression, and the Microbiome: A Role for Gut Peptides